Literature DB >> 32067513

Safety of the current drug treatments for vitiligo.

Torello Lotti1, Komal Agarwal2, Indrashis Podder3, Francesca Satolli4, Martin Kassir5, Robert A Schwartz6, Uwe Wollina7, Stephan Grabbe8, Alexander A Navarini9, Simon M Mueller10, Mohamad Goldust10,11,12.   

Abstract

Introduction: Vitiligo is an acquired depigmenting skin disorder adversely affecting the patient's quality of life. Despite the presence of several treatment modalities, ranging from medical to physical to surgical options, none is curative. Each modality has its own drawbacks and side effects. Thus, the treatment modality needs to be tailored for each individual patient taking into consideration the disease characteristics and also its efficacy and safety to obtain a favorable risk-benefit ratio.Areas covered: This review highlights the different treatment modalities utilized in vitiligo up until 4 November 2019 along with their adverse effects and contraindications, if any.Expert opinion: All the medications have their own adverse effects and contraindications. We have included the most commonly used topical corticosteroids, which may result in striae, cutaneous atrophy, and tachyphylaxis, to the recently introduced biologics, which may induce hypersensitivity reactions, systemic toxicities, and even malignancies. However, more long-term studies are needed to assess the safety of these medications, especially the newer ones, to provide a safe and effective treatment for this disorder.

Entities:  

Keywords:  Vitiligo; contraindications; safety; treatment

Mesh:

Substances:

Year:  2020        PMID: 32067513     DOI: 10.1080/14740338.2020.1729737

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  1 in total

Review 1.  Updates and new medical treatments for vitiligo (Review).

Authors:  David Emmanuel Kubelis-López; Natalia Aranza Zapata-Salazar; Salvador Luis Said-Fernández; Celia Nohemí Sánchez-Domínguez; Mauricio Andrés Salinas-Santander; Herminia Guadalupe Martínez-Rodríguez; Osvaldo Tomás Vázquez-Martínez; Uwe Wollina; Torello Lotti; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.